Skip to content
Monday 10 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,856.24
-0.41%
DAX
26,362.31
+0.16%
CAC 40
8,714.69
0.00%
STOXX 50
6,538.82
+0.23%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

GSK

  • RBS chairman Sir Philip Hampton will succeed Sir Christopher Gent at GSK earlier than expected

    February 26, 2015

    Outgoing RBS chairman Sir Philip Hampton is being parachuted into a new job at GlaxoSmithKline (GSK) earlier than expected and will spend three months as chairman of both companies. The departure of the drugmaker’s current chairman Sir Christopher Gent was revealed last year, with Hampton due to take the reigns from 1 September. Hampton will [...]

  • How GSK and AstraZeneca might stop advancing treatments if drug spend is reduced

    February 19, 2015

      Big pharmaceutical companies thrive off the invention of new drugs, but their success relies on those drugs being purchased at the end of the line.    If the maximum amount spent by the NHS on new medicines was seriously lowered, as a report released today suggested, it would not only limit access to some [...]

  • Viiv Healthcare IPO: Banks onboard for GlaxoSmithKline’s £17bn pharma float

    February 4, 2015

    Pharma giant GlaxoSmithKline (GSK) has hired banks to analyse the pros and cons of a float of its HIV medicines business next year, in what would be the one of the UK’s biggest initial public offerings of the last decade. Chief executive Sir Andrew Witty said banks, believed to be Citi, Goldman Sachs and Morgan [...]

  • GSK takes over in the Ebola race: Experimental vaccine Sent to Liberia for main tests

    January 23, 2015

    Trials of GSK's experimental vaccine to prevent Ebola are about to begin in west Africa.    Some 300 doses will be transported to Monrovia, capital of Liberia, and the intention is to inject the first subject within the next few weeks. Ultimately, researchers plan to inoculate 30,000 volunteers, including health-workers.    The vaccine was created [...]

  • Johnson & Johnson catches up with GSK in race to develop Ebola vaccine – human safety trials begin in Oxford

    January 6, 2015

    Johnson & Johnson has started human trials of its new Ebola vaccine, which is intended to stop the spread of the epidemic that has already killed thousands of people in west Africa.    Trials are taking place on 72 people at Oxford University, and similar tests will soon get going in the US and three [...]

  • Glaxo abandons sale of its older drugs portfolio

    December 4, 2014

    British pharma giant GlaxoSmith-Kline revealed late yesterday afternoon that it would not be going ahead with the sale of a portfolio of old drugs that had been valued at over $3bn (£1.9bn). Chief executive Sir Andrew Witty had talked up interest in the selection of off-patent treatments last summer, with several private equity firms believed [...]

  • How does GSK’s new Ebola vaccine work? US safety trials show immunity with no side effects

    November 27, 2014

    GSK's Ebola vaccine could soon be used to protect people against the disease in west Africa, after trials in the US gave volunteers immunity to the deadly virus without causing any negative side effects.    Some 20 healthy people were administered the vaccine in an early-stage clinical trial, and all developed antibodies within four weeks, [...]

  • Is there a cure for Ebola? GlaxoSmithKline sees success in first human vaccine trials

    November 26, 2014

    The first Ebola vaccine to be tested on humans has shown promising results in early trials, GlaxoSmithKline (GSK) said last night. GSK said the vaccine, co-developed with the US National Institutes of Health, was “well-tolerated and produced an immunological response in each of the 20 healthy adult volunteers in the US who received it”. The [...]

  • GSK to start Ebola vaccine trials in west Africa next month

    November 13, 2014

    GSK says its Ebola vaccine will begin trials in west Africa next month.   Safety clinical trials will take place in Mali at a treatment centre run by the charity Medicins Sans Frontieres (MSF), which has been at the forefront of tackling the virus since the epidemic started in December last year. It is hoped [...]

  • Is there a cure for Ebola? Inhaled vaccine could provide answer to injection worries of GSK, NewLink and Johnson & Johnson

    November 4, 2014

    Could a newly-developed inhaled vaccine soon be used to stop the spread of Ebola between humans in west Africa? Developed by a team of researchers at a university in Texas, it has already been shown to provide long-term protection for non-human primates against the deadly virus.   The formulation took seven years to create, and [...]

Posts pagination

  • Previous
  • Page 1
  • …
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • …
  • Page 22
  • Next

Trending Articles

  • Back to basics: Sainsbury’s gradual retreat from the British high street

  • Thames Water faces fresh threat to survival after pensions regulation breach

  • Hargreaves Lansdown orders staff back to office

  • FTSE 100 Live: Intel, Arm shares slide; Oil climbs higher

  • PwC’s Embankment HQ to get major makeover ahead of Canary Wharf move

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook